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Introduction
The gap in medical knowledge between ischaemic and
haemorrhagic type of stroke is surprising. Whereas the
ischaemic side has been extensively evaluated by an
impressive amount of pathophysiological studies as well as
of clinical trials, intracerebral haemorrhage (ICH) has been
so far a relatively neglected medical issue, addressed by a
handful of trials.
Such a difference is even more surprising if we consid-
er some epidemiological features of this disease. ICH is a
common disorder, with an estimated overall incidence
between 12 and 15 cases per 100 000 people each year
[1–5], i.e., 37 000–50 000 cases each year in the USA [2,
3]. The most striking data, however, is its 6-month mortal-
ity, ranging between 30% and 55% and increasing up to
67% in patients receiving oral anticoagulant therapy
(OAT). Moreover, it is a seriously disabling illness, as
80%–90% of survivors are left with dense neurological
deficits [1–5].
In this review we will first examine the pathophysiolo-
gy of ICH in patients with normal haemostasis and in
patients in anticoagulant or antiplatelet treatment, and then
we will consider the current therapeutic options for both
groups of patients.
Pathophysiology of ICH in patients with normal
haemostasis
ICH can be defined as an acute and spontaneous bleeding
into the brain parenchyma [5]. In more than two-thirds of
cases ICH is classified as primary, as it occurs from spon-
taneous rupture of small vessels damaged by hypertension
(60%–70% of cases) or amyloid angiopathy (15% of
cases). In a minority of patients ICH results from trauma,
vascular abnormalities (arteriovenous malformations and
aneurysm) or other causes listed in Table 1. The incidence
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Abstract Intracerebral haemorrhage (ICH) is the deadliest
form of stroke, carrying  a mortality rate between 30% and
55%, increasing to 67% in patients on oral anticoagulant
therapy (OAT). Despite its relevant incidence, the treat-
ment of ICH has been until recently a largely neglected
item, addressed by only a few trials. Early treatment of
ICH in non-anticoagulated patients with recombinant acti-
vated factor VII (rFVII) has been demonstrated to be able
to limit the growth of the haematoma, but such a promis-
ing result requires further confirmations. In ICH patients
receiving OAT a prompt reversal of the anticoagulant
effect should be warranted in order to reduce the conse-
quences of this dreadful adverse event. In clinical practice,
however, just a small proportion of anticoagulated patients
receive this treatment, probably because of the fear of
thromboembolic complications. It is now time to check our
way of thinking about ICH, regarding and treating it as a
compelling medical emergency.
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of ICH increases exponentially with age, is higher in men
than in women and is strongly increased by antiplatelet or
anticoagulant therapy [6].
ICH has been considered until recently a monophasic
event, in which blood clotting and the tampon effect of the
surrounding tissues were able to self-limit the extent of the
injury. Such a pathophysiological picture has probably con-
ditioned the medical approach to such a disease, usually
oriented to a minimalist, if not nihilistic, attitude. The land-
mark prospective study of Brott et al. [7] was the first to
demonstrate that an increase in haematoma volume of more
than 33% occurs within 3 h from the ICH onset in more
than one third of patients, even in the absence of coagula-
tion defects. This process, known as early haematoma
growth, is of paramount clinical relevance, as both mortal-
ity and functional outcome have been demonstrated to be
strictly related to the haematoma volume [8–10]. On these
pathophysiological grounds it is very attractive to hypothe-
sise that an early haemostatic treatment might stop ongoing
bleeding  and improve outcomes [11].
A further mechanism involved in neurological deterio-
ration is the process of perihaematomal brain injury. The
development of perihaematoma oedema starts early, in
most cases within 3 h from ICH onset, and it progressively
increases for at least 72 h [9, 11]. Although apparently
paradoxical, the main role in promoting perihaematoma
oedema is played by thrombin. Activation of the coagula-
tion cascade with release of thrombin during clotting,
indeed, appears to be the triggering event that initiates for-
mation of brain oedema, because thrombin itself is able to
activate both inflammation and cytotoxicity and disrupts
the blood–brain barrier [12–14].
Pathophysiology of ICH in patients receiving
antithrombotic therapies
Any antithrombotic treatment negatively affects both the
incidence and the prognosis of ICH. Oral anticoagulant
treatment (OAT) significantly increases the risk of ICH in
comparison with patients who are not on OAT, leading to an
estimated incidence as high as 1.8%/year [15–19]. Risk
factors for ICH in OAT patients are listed in Table 2. The
relationship between intensity of anticoagulation and the
risk of ICH is a relevant point. Although International
Normalised Ratio (INR) values exceeding 3.5–4 are associ-
ated with a higher risk of ICH, the majority of OAT-related
ICH (OAT-ICH) occur when the INR is within the thera-
peutic range [20–22]. Oral anticoagulation with INR to
maintain levels between  2 and 3, even if carefully regulat-
ed, increases several times the relative risk of ICH, with an
absolute risk ranging from 0.3 to 0.6%/year [17–22].
Thus, OAT not only increases the risk, but also worsens
the prognosis of ICH, increasing its severity as well as the
likelihood of death [23–25]. Although the dynamics of
haematoma expansion in OAT-ICH is not fully established,
it is reasonable to assume that the persistent coagulopathy
may lead to haematoma growth over a longer period than in
non-OAT patients [25]. This finding is of great clinical rel-
evance, as it provides the pathophysiological rationale for
the treatment of OAT-ICH, which should be aimed to
immediately reverse the anticoagulant effect in order to
limit haematoma expansion.
In the general perception antiplatelet drugs are very
safe, carrying only a small risk of gastrointestinal adverse
effects. This perception is not at all correct, because aspirin
(the most widely used antiplatelet drug) carries a significant
risk of ICH, ranging between 0.2% and 0.3%/patient/year,
slightly higher than the estimated absolute rate in the gener-
al population [6], not receiving aspirin. Such a figure is fur-
ther worsened by the combination of clopidogrel and
aspirin, which may increase ICH by a clinically relevant
magnitude in patients with cerebrovascular diseases [26,
27]. Moreover, it has been recently demonstrated in a popu-
lation-based study that regular aspirin use before ICH onset
increases 2-fold the risk of death, independently from the
severity of bleeding [28]. Similar findings had already been
obtained in previous studies [29, 30], although they were not
confirmed in a very recent one [31]. A possible explanation
for the observed increase in mortality is an early enlarge-
ment of haematoma because the impairment of the
haemostasis lasts for a few days even after aspirin with-
drawal [28, 30].
Finally, the association of warfarin and aspirin should
be considered. This is a very common clinical problem, as
Table 1 Causes of intracerebral haemorrhage
Primary intracerebral haemorrhage (78%–88% of cases)
• Chronic hypertension (60%–70% of cases)











• Cocaine or heavy alcohol use
• Haemorrhagic conversion of ischemic stroke
Table 2 Risk factors for developing intracerebral haemorrhage dur-
ing oral anticoagulant therapy
• Age (especially over 75 years)
• Hypertension (especially systolic blood pressure >160 mmHg)
• Previous stroke
• INR levels
• Concomitant use of antiplatelet drug
• Cerebral amyloid angiopathy
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it has been estimated that approximately 20% of patients
taking warfarin for atrial fibrillation also receive
antiplatelet drugs for concomitant coronary heart disease
[32]. Data about the risk of ICH during this combination
therapy are conflicting, as some studies show an increased
risk when anticoagulant and antiplatelet therapy are com-
bined [33, 34], whereas others do not [35, 36]. Although the
inconsistency of data precludes any evidence-based firm
conclusion, it seems reasonable to assume that the ICH risk
is further increased by the association of warfarin and
antiplatelet drugs.
Emergency treatment of ICH
Recent insights into the pathophysiology of ICH are
expected to profoundly modify the treatment of this dis-
ease. The key message strongly emerging from the current
literature is that “time is brain” [37], and therefore ICH
should be regarded and treated as a compelling medical
emergency. It is therefore time to leave the minimalist, if
not nihilistic, approach to the therapy of ICH that has been
the predominant attitude in the past.
Emergency management of ICH patients includes air-
way management, control of intracranial pressure and treat-
ment of hypertension [38]. The latter point is of great rele-
vance, as extreme hypertension is a common finding with-
in the first hours from ICH onset, and raised blood pressure
negatively affects ICH outcome [39, 40], although a recent-
ly published study fails to find such an association [41].
Treatment of hypertension can be performed in an emer-
gency setting by intravenous boluses of labetalol (10–80
mg bolus every 10 min, up to 300 mg), whereas in intensive
care units blood pressure can be controlled by continuous
infusion of labetalol, esmolol or nicardipine [3]. Sodium
nitroprusside should be avoided in this setting because of
its tendency to raise intracranial pressure through cerebral
vasodilatation [42]. As far as intracranial pressure control is
concerned, emergency measures to lower it are required for
comatose patients as well as for those with signs of cerebral
herniation [38]. However, no anti-oedema treatment
(steroids, osmotic diuretics, haemodilution) has been
demonstrated to reduce mortality and disability in these
patients [43–45].
Alongside these supportive therapies should stand aeti-
ological treatments aimed to reduce haematoma size, for
instance by surgical removal. The effectiveness of surgical
removal of haematoma is still a controversial issue, namely
if localised in the basal ganglia, the most common site of
ICH. Current treatment strategies usually reserve surgical
treatment for those patients with subcortical or cerebellar
haematoma of more than 3 cm in diameter and impaired
consciousness. However, most patients cannot be included
in this category, and the benefit of surgical evacuation is not
clearly assessed for these cases. The recently published
STICH trial included 1033 ICH patients for whom the
attending neurosurgeon was uncertain about the choice
between surgical or conservative treatment [46]. The
STICH trial showed no benefit in outcome from surgery
performed within 24 h from randomisation after supraten-
torial ICH [46]. This result does not mean that surgery is
always useless in ICH, as patients who were considered to
have benefited from early haematoma evacuation were
excluded from the study. However, data from the STICH
trial are challenging the views that early neurosurgery can
be an effective treatment for every form of ICH.
Despite this disappointing finding of the STICH trial,
there are new hopes for an effective medical treatment of
this dreadful type of stroke.
Since its approval by the Food and Drug Administration
in March 1999 for the treatment of bleeding in haemophil-
ia patients with inhibitors to factor VIII and IX and in
patients with acquired haemophilia, recombinant activated
factor VII (rFVIIa) has been regarded with great interest by
physicians as a potential “pan-haemostatic” agent able to
control bleeding in patients with both inherited and
acquired coagulation disorders [47]. Administration of a
high dose of rFVIIa results in a huge increase of VIIa level,
compared to the physiological state, causing faster and
higher thrombin generation by binding of TF exposed at the
site of endothelial injury. In addition, at pharmacological
doses (26–50 nM), rFVIIa can bind to the surface of acti-
vated platelets and directly activate FX in the absence of
TF. rFVIIa has been also shown to be an effective promot-
er of haemostasis in bleeding patients with an otherwise
normal coagulation system [47]. Many biochemical fea-
tures of rFVIIa make it very attractive for an early haemo-
static therapy of ICH: the very rapid action mainly
localised to the site of vascular injury, the short half-life of
2.5 h, and a good safety profile, at least in haemophilia
patients [48].
Hence, a recent randomised, placebo-controlled, dose-
ranging study was conducted to assess the use of rFVIIa in
non-coagulopathic patients with ICH [49]. In this trial 399
patients with primary ICH diagnosed by CT within three
hours after the onset of symptoms were randomly assigned
to receive placebo or a single intravenous dose of 40, 80 or
160 µg/kg of rFVIIa within one hour after the baseline CT
scan. Patients on OAT were excluded from the study. The
primary end-point was the percent increase of the volume
of ICH at 24 h; secondary end-points were clinical out-
comes (survival, disability evaluated according to Modified
Rankin, Extended Glasgow Outcome and National
Institutes of Health Stroke scale and Barthel Index as well
as percent of serious thromboembolic events) at 90 days.
Results are extremely encouraging, as patients treated with
rFVIIa show a significantly lower increase in the
haematoma volume compared to placebo-treated patients
(relative, 14% vs. 29%, p=0.01; absolute, 4.2 vs. 8.7 ml,
p=0.01). A dose response is evident, as the difference is sig-
nificant for higher doses (160 µg/kg), but not for interme-
diate and lower doses (80 and 40 µg/kg). More interesting-
ly, the reduction in the haematoma growth is accompanied
by improved survival and better clinical outcomes in the
treated group. Such a beneficial effect is impressive: 90
days mortality is reduced in the rFVIIa group from 29% to
18%, with an odds ratio for survival of 1.8 and a number
needed to treat of approximately 9. Equally striking is the
effect on severe disability, with a 13% absolute reduction
on unfavourable outcomes measured according to the
Modified Rankin Scale (odds ratio for improvement 2.2,
p=0.0004) and a more than double score on Barthel Index
(60.0 vs. 25.0, p=0.006) for the treatment group. On the
other hand, fears about the thrombogenic potential of such
a powerful haemostatic drug are at least partially borne out.
Arterial thromboembolic serious adverse events occur sig-
nificantly more frequently in the rFVIIa-treated than in
placebo-treated patients (5% vs. 0%), primarily as myocar-
dial ischaemic events and ischaemic stroke, half of them
occurring  in the largest dose group. However, most
patients recovered from these complications, and the over-
all frequency of fatal or seriously disabling ischaemic
events does not differ between rFVIIa and placebo.
How can we transfer the results of this innovative trial
into everyday clinical practice? Should we modify our guide-
lines in order to assure every ICH patient has early rFVIIa
treatment? If the question is so radically asked, the answer is
certainly not, as stated by a recent systematic review from
the Cochrane Library [50]. Many issues suggest caution
before recommending rFVIIa as the standard of treatment for
ICH. First, in this trial there was no adjustment for blood
pressure, a factor known to affect the outcome of ICH
[38–40], although the trend of this parameter did not differ
among the treatment groups. In future trials, great attention
should be paid to this issue in order to identify possible inter-
actions of rFVIIa with blood pressure that could modify the
magnitude of benefit of this drug in ICH patients. Second,
treatment with rFVIIa is effective only in patients treated
within 3 h of symptoms onset, whereas in patients treated
later no difference in the haematoma growth is found com-
pared to the controls [51]. This suggests that the time win-
dow for this intervention is very narrow, and only a subset of
ICH patients could benefit from such a treatment. Indeed, a
recently published population-based cohort study estimates
that only 13%–18% of ICH patients would have qualified for
treatment with rFVIIa by Meyer’s trial criteria [52], 2–3
times the rtPA eligibility rate of ischaemic stroke patients
[53]. Although the absolute number of treated patients would
likely be less than those with ischaemic stroke, it can be pos-
tulated  that in the USA between 5000 and 9000 ICH patients
could be eligible for rFVIIa treatment each year. Such an
impressive figure is expected to raise both organisational and
financial problems for health care services, but more than
1200 lives may be saved annually [52].
Finally, some concerns have been raised about a possi-
ble increase of perihaematoma oedema because of rFVIIa-
mediated enhanced thrombin generation, as thrombin has
been implicated in the pathogenesis of oedema formation in
acute ICH [13, 14]. However in this trial [51] the mean vol-
ume of ICH, perihaematomal oedema and intraventricular
haemorrhage at 72 h were significantly lower in the rFVII
than in the placebo group (mean difference from placebo
–11 ml, p=0.003), arguing against an oedema-enhancing
effect of the haemostatic treatment.
In conclusion, rFVIIa must be viewed as a promising
new therapeutic approach to ICH. Hopefully the ongoing
phase III rFVIIa in Acute Hemorrhagic Stroke Treatment
(FAST) trial will clarify some of these relevant issues, such
as the most effective and safe dose and  the potential inter-
actions of rFVIIa with blood pressure control.
Treatment of ICH in anticoagulated patients
ICH is the most fearful and potentially fatal complication
of OAT. Although the incidence, time course and rate of
haematoma expansion of OAT-ICH are not well defined, it
seems reasonable to expect that a rapid restoration of the
haemostatic ability will help to stop ongoing bleeding, thus
preventing haematoma growth. Against this sensible
approach stands the fear of thromboembolic complications
because of discontinuation of antithrombotic therapy. The
resultant of such opposite forces is often a null vector. In
most cases the therapeutic approach is therefore restricted
to simply waiting for the disappearance of the anticoagu-
lant effect, even though this can last for several days.
Such a nihilistic approach is particularly astonishing as
many guidelines suggest (although with weak strength of
recommendations because of the lack of solid evidence)
that patients with diagnosed warfarin-associated ICH
should receive emergent reversal of anticoagulation
[54–58]. However, lack of well designed trial of good
methodological quality makes it  very difficult to formulate
strong recommendations, leaving the optimal treatment  of
OAT-ICH an already open issue. Treatment options include
the use of vitamin K, fresh frozen plasma (FFP), prothrom-
bin complex concentrates (PCC) and rFVIIa [38].
There is a general consensus on vitamin K administration
as the first step of warfarin reversal, but as it takes several
hours to achieve its full therapeutic effect, concomitant
administration of coagulation factors is required in order to
immediately reverse the anticoagulant effect. FFP contains
all coagulation factors, and it is generally assumed that 1
ml/kg body weight of FFP increases the levels of coagulation
factors by 1–2 IU [59]. It is a common experience that the
FFP volume required to ensure anticoagulation reversal may
vary between 800 and 3500 ml [19]. The latter large volumes
may cause a circulatory overload, namely in patients with
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impaired cardiac function, which represent a substantial pro-
portion of warfarin-treated patients. FFP carries other draw-
backs, such as the need for compatibility testing, the time
required for thawing and a small, but definite, risk of adverse
reactions, including transfusion-associated lung injury,
blood-borne infections and allergic reactions [59].
Many of these problems can be overcome by PCC use.
PCC contain coagulation factors II, IX, X and VII (the latter
not in preparations licensed in Italy) in a concentrated form
and in well standardised amounts. These products are virally
inactivated, and therefore are safer than plasma with respect
to the risk of transmission of the human immunodeficiency,
hepatitis B or hepatitis C virus. A thrombogenic effect has
occasionally been reported, but reports dealt with patients at
very high thromboembolic risk [60]. Moreover, only a very
small volume of product is required in order to ensure com-
plete reversal of anticoagulation: a standard dose of 30–50
IU/kg of PCC consisted of 50–150 ml of reconstituted prod-
uct, which can be administered within a few minutes.
Studies on small numbers of patients suggest that PCC
correct a prolonged INR more rapidly and completely than
FFP [61, 62] and reduce the risk for haematoma growth
[61], although they does not appear to improve long-term
outcome [63, 64].
The already reported biochemical features of rFVIIa
make it a promising candidate also for OAT-ICH treat-
ment, but so far the data on this subject are very limited
[65, 66]. The very short half-life of rFVIIa can be a seri-
ous drawback for the treatment of bleeding in anticoagu-
lated patients. Indeed, rFVIIa action is expected to stop
long before the vitamin-K-dependent factors are restored,
thus exposing patients to a potentially dangerous time
window of persistent anticoagulation.
Patients with OAT-ICH urgently need a definitive
improvement in the treatment of their severe complication.
Very recently published data show that in Italy, only about a
third of patients admitted to emergency departments with
warfarin-related ICH undergo procoagulant medical treat-
ment [67]. Moreover, a recently published retrospective
review of a single-centre experience on the management of
OAT-ICH found a strikingly long delay in time to interven-
tion, as a median period of 210 min is required from com-
puted tomography to FFP administration for patients referred
from other hospitals [68]. The Authors found that every 30-
min delay in FFP administration is independently associated
with a 20% decrease in the probability of successful INR
reversal within 24 h [68]. Once again, “Time is brain” [37],
and each hospital should have protocols for the treatment of
ICH, as they do for ischaemic stroke. Table 3 reports a pro-
tocol recently proposed by FCSA (Italian Federation of
Anticoagulation Clinics) for the emergency management of
ICH in anticoagulated patients.
Many issues remain to be clarified in OAT-ICH, and
probably the most compelling is if and when to restart anti-
coagulation following the development of such a serious
adverse effect of warfarin therapy. There is no strong scien-
tific evidence that can help the physician in this difficult
decision, which should be made on an individual patient
basis, carefully balancing haemorrhagic and thromboembol-
ic risks. As a rule, the risk of recurrence is considerably
greater in lobar than in deep hemispheric ICH [69], reflect-
ing a different underlying pathophysiology: hypertension in
the former, and cerebral amyloid angiopathy in the latter
[70]. The latter disorder is characterised by the deposition of
Table 3 Protocol for the emergency management of intracerebral haemorrhage in anticoagulated patients
In anticoagulated patients with suspected/possible ICH:
a. Provide a venous access of adequate size
b. Provide a blood sampling for routine test, including:
i. Blood count including platelet count
ii. Prothrombin time – International Normalised Ratio (PT-INR)
iii. Activated partial thromboplastin time (APTT)
iv. Serum creatinine
c. Perform a cerebral computed tomography (CT) in every symptomatic case or following head trauma. The CT should be repeated
after a few days if negative or in case of persisting/arising symptoms.
d. If the CT is positive for intracranial haemorrhage it is MANDATORY to immediately restore normal haemostasis. Then:
i. Withhold warfarin therapy 
ii. Give vitamin K1 (10 mg by slow IV infusion)
iii. Give prothrombin complex concentrates at the following doses:
1. 20 IU/kg if INR<2.0
2. 30 IU/kg if INR 2.0–4.0
3. 50 IU/kg if INR >4.0
iv. If PCC are unavailable, give fresh frozen plasma 15–20 ml/kg. In this case, consider the concomitant administration of diuret-
ics in order to prevent circulatory overload.
v. Control PT-INR at the end of the infusion and repeat PCC (or FFP) if PT-INR>1.5
vi. Provide prophylaxis of venous thromboembolism by mechanical methods (graduated compression stockings or intermittent
pneumatic compression)
The decision of if, and when, to restart anticoagulation should be made on an individual patient basis, carefully balancing thromboem-
bolic and bleeding risk. As a rule, prophylactic doses of low molecular weight heparins can be safely administered after 3 days and fol-
lowing a normal CT scan.
amyloid peptide in small- and medium-sized blood vessels
of the brain, thus resulting in vascular fragility. The clinical
syndrome is typified by spontaneous lobar haemorrhage in
elderly patients, usually less severe than hypertensive ICH.
However, the recurrence rate is considerably higher in
patients with lobar ICH and probable amyloid angiopathy
(5%–15% patients/year) than in those with hypertensive ICH
(2%/year when blood pressure is well controlled).
On these grounds it would seem reasonable to advise
against restarting OAT following a lobar ICH. However,
this does not mean that for the vast majority of patients
with deep hemispheric haemorrhage anticoagulation thera-
py can be recommended, with a possible exception for
patients at very high risk of ischaemic stroke [71].
Further clarification of risk factors for developing OAT-
ICH may help to clarify the risk-benefit analysis of war-
farin administration in individual patients. Genetic risk fac-
tors may have a role in this effort, as the possession of
apolipoprotein E (apoE) ε2 or ε4 allele appears to be asso-
ciated with increased risk of lobar ICH and recurrent ICH
resulting from cerebral amyloid angiopathy [72]. In addi-
tion, genetic polymorphisms have been identified that pre-
dispose to decreased dose requirements for warfarin and
may predispose to increased risk for high INR [73, 74].
Finally, remember the profound influence of blood pressure
control upon the prevention of ICH. In a recently published
randomised trial involving patients on either antiplatelet or
anticoagulant therapy, haemorrhagic stroke rate is halved
by a mean 9 mmHg reduction in systolic blood pressure
[75]. This very simple and inexpensive intervention is the
first proven preventive therapy for patients with a history of
haemorrhagic events, and should therefore be extended to
every patient receiving antithrombotic drugs.
Conclusions
Many issues regarding the appropriate treatment of ICH
need to be clarified by properly designed trials.
Nevertheless, there is a growing body of literature provid-
ing new insights into this serious disease and giving new
realistic hopes to ICH patients. The goal of substantially
improving the outcome of this dreadful disease is certainly
demanding, but is now  more feasible than a few years ago.
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